

# 1 Compartmentalized sesquiterpenoid biosynthesis and 2 functionalization in the *Chlamydomonas reinhardtii* plastid

3 Sergio Gutiérrez, Sebastian Overmans, Gordon B. Wellman, Kyle J. Lauersen\*

4 Bioengineering Program, Biological, Environmental Sciences and Engineering  
5 Division (BESE), King Abdullah University of Science and Technology (KAUST),  
6 Thuwal, Saudi Arabia.

7 \*Corresponding author: [kyle.lauersen@kaust.edu.sa](mailto:kyle.lauersen@kaust.edu.sa)

8 **Keywords:** Terpenoid biosynthesis; Metabolic engineering; *Chlamydomonas*  
9 *reinhardtii*; Chloroplast; Cytochrome P450.

## Abstract

Terpenoids play key roles in cellular metabolism, with some organisms having evolved expanded terpenoid profiles for specialized functions such as signaling and defense. Many terpenoids have applications in pharmaceuticals, fragrances, and agriculture, but their harvest from natural sources can be challenging. Heterologous production of specialty terpenoids in microbial hosts offers an alternative, using terpene synthases and further enzymatic decoration to expand chemical complexity and functionality. Here, we explored the heterologous production of 10 different sesquiterpenoids (STPs, C<sub>15</sub>) and their further biofunctionalization mediated by cytochrome P450s (CYPs) in the green alga *Chlamydomonas reinhardtii*. STP synthases were expressed from the nuclear genome and localized to the algal plastid, coupled with co-expression of selected CYPs. STP production in the plastid was supported by farnesyl pyrophosphate synthase fusions to STP synthases, and CYPs were modified for soluble localization in the plastid stroma by removing transmembrane domains. Various target CYPs were screened for STP functionalization in the alga, and different product ratios were generated based on trophic modes. Overall STP yields ranged between 250-2500 µg L<sup>-1</sup> under screening conditions, with CYP-mediated functionalization reaching up to 80% of accumulated heterologous STP products. Living two-phase terpenoid extractions with different perfluorinated solvents revealed variable performances based on sesquiterpenoid functionalization and solvent type. This work demonstrates the feasibility of generating heterologous functionalized terpenoid products *in alga* using soluble, plastid-localized CYPs without reductase partners. However, overall improvements in photobioreactor cultivation concepts will be required to facilitate the use of algal chassis for scaled production.

## Significance Statement

This study demonstrates the feasibility of producing and modifying heterologous terpenoid products in the algal plastid using sesquiterpene synthases (STPS) and soluble cytochrome P450s (CYPs). We show that algal cultivation conditions influence the composition and ratios of functionalized terpenoid products, which can be extracted through solvent-based 'milking' during growth. The reducing equivalents that enable CYP activity in the plastid appear derived from photosynthetic electrons without requiring the co-expression of a cytochrome P450 reductase (CPR) partner, simplifying engineering strategies. As algae can be cultivated with minimal inputs (trace elements, light, and CO<sub>2</sub>) from sources like wastewater, this approach offers the potential for sustainable production of complex specialty terpenoid chemicals.

# 1. Introduction

Terpenoids are one of the most diverse classes of natural organic compounds, playing crucial roles in biological processes across all domains of life <sup>1, 2</sup>. These molecules function in photoprotection, photosynthesis, electron transport, defense, and signaling <sup>1, 3, 4</sup>. Terpenoids have wide-ranging applications in medicine, flavoring, and fragrances <sup>4, 5</sup>. However, their structural complexity poses challenges for chemical synthesis <sup>2, 6</sup>. Consequently, terpenoid production often relies on extraction from plant sources, resulting in low yields and impurities <sup>3, 6</sup>. Harvesting terpenes from native organisms presents additional issues, as natural sources cannot meet demand due to slow growth rates or cultivation difficulties <sup>2, 3</sup>, and excessive harvesting can cause ecological disruption <sup>4</sup>. To address these issues, biotechnological approaches through metabolic engineering of microbes have been explored as alternatives for terpenoid production <sup>6</sup>. While conventional strategies employ fermentative microorganisms, photosynthetic microalgae offer unique advantages due to their native terpenoid biosynthesis pathways and light-driven metabolism <sup>6-8</sup>.

Terpenoid biosynthesis begins with the formation of five-carbon ( $C_5$ ) isoprene units: isopentenyl pyrophosphate (IPP,  $C_5$ ) and its isomer dimethylallyl pyrophosphate (DMAPP,  $C_5$ ) <sup>2</sup>. These units are generated through the mevalonate (MVA) pathway or the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway <sup>1, 2</sup>. Prenyltransferases catalyze the sequential addition of IPP and DMAPP to produce linear precursors, including geranyl pyrophosphate (GPP,  $C_{10}$ ), farnesyl pyrophosphate (FPP,  $C_{15}$ ), and geranylgeranyl pyrophosphate (GGPP,  $C_{20}$ ) <sup>2</sup>. Terpenoid synthases (TPS) convert these precursors into cyclic terpenoid skeletons through complex reactions <sup>6</sup>. This process yields various terpenoid structures, such as monoterpenoids ( $C_{10}$ ), sesquiterpenoids ( $C_{15}$ ), diterpenoids

74 (C<sub>20</sub>), triterpenoids (C<sub>30</sub>), and tetraterpenoids (C<sub>40</sub>)<sup>9</sup>. The resulting skeletons often  
 75 undergo further modification through functionalization catalyzed by enzymes like  
 76 acetyltransferases, carboxylases, and cytochrome P450 (CYP) monooxygenases  
 77 <sup>2, 8</sup>. CYPs are found overexpressed in tissues where terpenoids accumulate,  
 78 allowing efficient substrate access and interaction with cofactors and redox  
 79 partners<sup>10</sup>.

80 This study investigates heterologous complex terpenoid biosynthesis in  
 81 *Chlamydomonas reinhardtii* by localizing sesquiterpene production and  
 82 functionalization reactions in the algal plastid. We leverage advances in  
 83 transgene design for robust expression, native terpenoid precursor supply in the  
 84 photosynthetic cell, and the redox environment of its plastid to generate  
 85 heterologous terpenoids and chemically functionalize them. By integrating  
 86 terpenoid biosynthesis and CYP-mediated functionalization into the plastid, we  
 87 aimed to leverage its chemical reduction potential to mediate functional group  
 88 addition to heterologous STPs without the expression of partnering cytochrome  
 89 P450 reductases (CPRs). We focused on fragrant sesquiterpenoids (STP, C<sub>15</sub>)  
 90 derived from agarwood and sandalwood, where minimal chemical modifications  
 91 to the terpenoid backbone can expand scent profiles. We evaluated the effects  
 92 of carbon sources on product formation and examined the behavior of produced  
 93 terpenoids when algal cultures interact with different extractants. By exploring  
 94 *C. reinhardtii* as a host for compartmentalized terpenoid production, this work  
 95 contributes to the development of light-driven methods for producing valuable  
 96 chemical compounds.

## 2. Results and Discussion

### 2.1. Sesquiterpenoid production from terpene synthases located in the cytoplasm or chloroplast

*C. reinhardtii* has shown promise for photosynthetic production of non-native terpenoids<sup>7, 11-16</sup>. This microalga produces all terpenoid precursors for photosynthesis and other cellular processes using only the MEP pathway in its plastid<sup>6</sup>. Recent advances in transgene design have improved the expression of nuclear-encoded transgenes, facilitating metabolic engineering efforts for non-native terpene production and elucidating the metabolic flexibility of the photosynthetic cell<sup>16, 17</sup>. Although *C. reinhardtii* lacks endogenous sesquiterpenoid (STP) synthases, it can be engineered to produce diverse STPs by redirecting carbon flux from cytosolic farnesyl pyrophosphate (FPP)<sup>12, 14, 15, 17-20</sup>. In contrast, FPP levels in the plastid are natively low but can be increased to produce heterologous STPs by overexpressing a native or non-native FPP synthase localized to this subcellular compartment<sup>12, 15, 18, 20</sup>.

We compared the yields of 10 sesquiterpene synthases (STPSs) expressed from the algal nuclear genome and localized to either the cytoplasm or the plastid. Plastid-targeted constructs were designed with C-terminal FPPS fusions, as previous studies have shown that free FPP levels in the plastid are minimal and FPPS fusion to STPSs does not enhance productivity in the cytoplasm<sup>14, 20</sup>. The cell line employed features a constitutive knockdown of the native squalene synthase, which competes directly for cytoplasmic FPP with the introduced STPSs<sup>12</sup>. This modification allowed us to compare yield variations under best-case production scenarios between the cytoplasmic STPSs and plastid-localized STPSs fused to FPPS. We evaluated three different construct designs (Fig. 1A–

C, SI Appendix, Table S1, File S1, and Fig. S1–S3): a cytoplasmic targeted STPS alone and two different plastid-targeted FPPS fusions to STPSs, either the from *Saccharomyces cerevisiae* (Erg20) or *Escherichia coli* (ispA). Many sesquiterpenoids were successfully produced, including aristolochene, valencene, selinene, santalene, bisabolol,  $\tau$ -cadinol,  $\alpha$ -cadinene,  $\beta$ -cadinene,  $\gamma$ -cadinene, murolene,  $\alpha$ -guaiene,  $\beta$ -guaiene,  $\delta$ -guaiene,  $\alpha$ -humulene, alloaromadendrene, valerianol, and patchoulol (Fig. 1D, SI Appendix, Files S2–S4) in both compartments, with yields ranging from ~250 to 2500  $\mu\text{g L}^{-1}$  (Fig. 1E, SI Appendix, Table S2, and Fig. S5). The yields of STPSs were comparable for each sesquiterpene product from both cytoplasm (STPS alone) and plastid-targeted (STPS-FPPS fusion) containing transformants (Fig. 1E, SI Appendix, Table S2, and Fig. S5). Plastid-localized bisabolol and cadinol synthases achieved higher levels of bisabolol and cadinol production than their cytoplasmic counterparts. Bisabolol (construct C07) reached 84  $\mu\text{g L}^{-1}$ , while cadinol (construct C08) produced 208  $\mu\text{g L}^{-1}$  in (Fig. 1E, SI Appendix, Table S2, and Fig. S5).

The choice of FPPS influenced production efficiency in an unpredictable manner for each STPS. We found that ispA fusion constructs C02–C11 (Fig. 1E; SI Appendix, Table S2, Fig. S3, and S5) yielded higher titers for aristolochene, valencene, selinene, guaiane, and valerianol than their Erg20 counterparts (B02–B11; Fig. 1E; SI Appendix, Table S2, Fig. S2, and S5). These results suggest that selecting the appropriate FPPS can enhance the production of specific STPs; however, iterative empirical testing for each target STPS-FPPS fusion is required<sup>21, 22</sup>. Next, we investigated whether the reducing environment of the plastid could mediate the chemical functionalization of heterologous STP products by co-expressing CYPs specific to these compounds.

## 2.2. Functionalization of heterologous sesquiterpenoids mediated by co-expression of plastid-targeted P450s

In native hosts, terpenoids undergo chemical modifications that enhance their complexity and biological activities<sup>14, 23</sup>. Metabolic engineering can recapitulate these reactions by expressing the corresponding metabolic pathway in a foreign host<sup>2, 4, 9, 24, 25</sup>. Cytochrome P450 monooxygenases (CYPs) commonly catalyze reactions that add hydroxyl or other functional groups to terpenoids. CYPs receive electrons from CPRs, typically on the cytoplasmic side of the endoplasmic reticulum (ER) membrane<sup>10, 19, 26</sup>. CYPs and CPRs contain transmembrane (TM) anchors and have been successfully expressed and shown to function in non-native hosts such as yeasts and tobacco<sup>10, 11, 27</sup>. Recent studies have demonstrated that when CYPs are expressed and localized in cyanobacteria or plant plastids, photosynthesis-derived electrons can replace CPRs in driving CYP reactions<sup>27-31</sup>.

As we produced reasonable amounts of STPs in the *C. reinhardtii* plastid by introducing STPS-FPPS fusions (**Fig. 1E, SI Appendix, Table S2, and Fig. S2–S3**), we aimed to use the redox potential of the plastid for their chemical functionalization<sup>10, 11, 19</sup>. For each STP studied, we co-expressed and targeted CYPs to the algal plastid that had predicted or were previously shown to be responsible for mediating their functionalization (**SI Appendix, Table S1, File S1, Fig. S2, and S4**). Transformants confirmed to express both STPS-FPPS fusion and heterologous CYPs were cultivated with solvent overlays, and the products were analyzed by GC-MS/FID. Changes in chromatogram peaks were observed for all strains with co-expressed CYPs compared to those expressing STPSs alone (**Fig. 2A, SI Appendix, Table S3, and Files S5–S6**). These changes indicate the



presence of sesquiterpenoid derivatives, confirming the successful modification of base STPs in the plastid through CYP co-expression. Functionalization efficacy varied among CYPs, with some producing the expected product for a specific STP, while others generated numerous side products or inefficiently synthesized target compounds (**Fig. 2A, 2B, SI Appendix, Tables S7–S8, and Files S5–S6**). As no CPR was co-expressed in these strains, the results indicate that electrons present in the plastid can drive these targeted chemical modifications of heterologous terpenoids<sup>10, 11, 14, 19, 25, 27</sup>. The exact electron donor is unknown, but it could be ferredoxin or simply the reducing environment of the plastid itself in illuminated conditions.

For each STPS-CYP combination, we identified one CYP which generated the target functionalization as predicted or desired (**Fig. 2B, 2C, SI Appendix, Tables S4, and S7–S8**). Functionalization efficiency, calculated as the total sum of new peaks relative to the original STPS abundance, varied among each (**Fig. 2C, SI Appendix, Fig. S7, Tables S3, and S5**). We observed the following conversions: (1) Aristolochene to aristolochone by CYP02 (UniProt: W6QP06) at  $45 \pm 21\%$  efficiency (mean  $\pm$  SD). (2) Valencene to nootkatone by CYP04 (UniProt: E1B2Z9) at  $58 \pm 18\%$  efficiency. (3) Santalene to bergamotol and santalol by CYP09 (UniProt: VR5EU4) at  $55 \pm 13\%$  efficiency. (4)  $\alpha$ -Cadinene,  $\beta$ -cadinene,  $\gamma$ -cadinene, and muurolene to muurolol and  $\alpha$ -cadinol by CYP10 (UniProt: A0A0N9H930) at  $51 \pm 8\%$  efficiency. (5)  $\alpha$ -guaiene,  $\beta$ -guaiene,  $\delta$ -guaiene,  $\alpha$ -humulene, and alloaromadendrene to  $\alpha$ -guaiol,  $\beta$ -guaiol, globulol, rotundone, and alloaromadendrene oxide by CYP12 (UniProt: E3W9C4) at  $66 \pm 19\%$  efficiency.

Selecting appropriate CYPs to ensure product formation remains challenging, and our screening suggests that empirical testing is necessary to determine the

correct combination (Fig. 3)<sup>10, 12, 19, 27</sup>. Each CYP also led to the formation of off-target products (Fig. 3A, SI Appendix, Tables S3–S4, and S7–S8). A heatmap of the major identifiable products illustrates the chemical diversity obtained with each CYP on tested STPs (Fig. 4, SI Appendix, Fig. S6, and Table S7–S8). Functionalization efficiency consistently remained below 80% (Fig 2C, SI Appendix, Table S4, and Fig. S7), indicating room for improvement, which may be attained in the future through the formation of metabolons or artificial STPS-CYP associations via enzyme engineering strategies<sup>10, 11, 24, 25, 28-31</sup>.

### 2.3. Carbon source effects on plastid sesquiterpenoid biosynthesis and functionalization

*Chlamydomonas* can grow on organic acetic acid, inorganic CO<sub>2</sub>, or both as carbon sources. The trophic mode of cultivation induces major rearrangements in cell architecture, prompting us to investigate the effects of these changes on the product profiles of our engineered strains<sup>32</sup>. Using the most effective STPS-CYP pairs, we analyzed products from solvent milking of strains grown under three illuminated conditions: CO<sub>2</sub> alone, acetate alone, or combined CO<sub>2</sub>+acetate (Fig. 5). Chromatograms revealed distinct STP and derivative profiles under these cultivation modes (Fig. 5, SI Appendix, File S6). Relative abundance data showed variations in sesquiterpenoid production and functionalization efficiency depending on the carbon source (Fig. 5, SI Appendix, File S6).

Aristolochene synthase + CYP02 (Fig. 5A, SI Appendix, File S6) exhibited three major peaks across all conditions. CO<sub>2</sub> alone and CO<sub>2</sub>+acetate conditions yielded higher relative abundances of the functionalized product than acetate alone. Valencene synthase + CYP05 (Fig. 5B, SI Appendix, File S6) primarily produced nootkatone, with two minor peaks under CO<sub>2</sub> and CO<sub>2</sub>+acetate conditions.

223 Nootkatone abundance was highest with CO<sub>2</sub> alone, followed by CO<sub>2</sub>+acetate,  
224 and lowest with acetate alone.

225 Santalene synthase + CYP09 (Fig. 5C, SI Appendix, File S6) produced multiple  
226 peaks, representing α/β-santol, bergamotol, and precursors. CO<sub>2</sub> alone yielded  
227 the highest relative abundance of functionalized products, while acetate alone  
228 showed the lowest. Cadinol synthase + CYP10 (Fig. 5D, SI Appendix, File S6)  
229 showed multiple peaks across all conditions. Acetate and CO<sub>2</sub>+acetate  
230 conditions produced higher relative abundances of functionalized products  
231 compared to CO<sub>2</sub> alone. The most diverse compound array was generated by  
232 guaiene synthase + CYP12 (Fig. 5E, SI Appendix, File S6). CO<sub>2</sub> and  
233 CO<sub>2</sub>+acetate conditions displayed greater peak diversity than acetate alone, with  
234 CO<sub>2</sub>+acetate showing the highest relative abundance of functionalized products.

235 These results indicate that a mixed carbon source strategy enhances  
236 sesquiterpenoid production and functionalization in *C. reinhardtii*. The  
237 combination of CO<sub>2</sub>+acetate generally resulted in higher relative abundances of  
238 functionalized products in growth conditions tested, likely due to higher cell  
239 densities (Fig 5, SI Appendix, File S6)<sup>8, 11, 25-27, 31</sup>. The variable peak intensities and  
240 product species observed here add complexity to the prediction of functionalized  
241 STP product outputs from engineered algal cultivation. Whether product profiles  
242 can be consistently tailored during scaled cultivations is still unknown.  
243 *Chlamydomonas* is not routinely cultivated phototrophically at scale, and research  
244 is ongoing to test methods of scaled extraction of engineered terpenoids through  
245 solvent milking<sup>33, 34</sup>. Future studies should address these limitations through  
246 production scale-up and long-term cultivation experiments with variable light  
247 regimes to assess production feasibility<sup>6, 14, 35</sup>.

## 2.4. Culture-solvent extraction efficiencies

Extracting non-native sesquiterpenoids from *C. reinhardtii* requires the culture to grow in contact with a biocompatible solvent<sup>5, 21, 23, 26, 31, 33, 34, 36-38</sup>. The choice of extraction solvent has environmental and economic implications for bioprocess designs<sup>39</sup>. While dodecane is a standard biocompatible solvent for lab-scale terpenoid extraction and quantification, perfluorinated solvents offer advantages in safety, stability, and reusability<sup>12, 33, 34, 37, 38, 40, 41</sup>. We recently reported a method to use perfluorinated solvents to extract algal-produced terpenoids<sup>12</sup>. This method allowed the subsequent transfer of terpenes from perfluorinated solvent to ethanol through liquid-liquid separation, enabling recycling of the clean perfluorinated solvent to algal culture and direct use of the ethanol-terpene mixture for fragrance applications.

Here, we evaluated a larger pool of perfluorinated solvents for their capacity to accumulate heterologous and chemically complex sesquiterpenoids produced by *C. reinhardtii* compared to dodecane (**Fig. 6, SI Appendix, Table S5**). Terpenoid accumulation was lower in all fluorinated solvents than in dodecane, and extraction efficiencies varied across solvents and sesquiterpenoid compounds (**Fig. 6, SI Appendix, Table S5**). This variability is likely due to individual differences in solvent and sesquiterpenoid properties, as each solvent is unique, and the sesquiterpenoids have structural differences<sup>12, 21, 33, 34</sup>. FC-40 and FC-770 demonstrated higher extraction capacities for bisabolol (32% and 31% compared to dodecane, respectively), while CFL7160 extracted aristolochene (15%) and selinene (16%) more effectively (**Fig. 6, SI Appendix, Table S5**)<sup>12-14, 18, 33, 34</sup>. We observed enhanced accumulation of -OH group-containing STPs in all FCs tested (**Fig. 6, SI Appendix, Table S5**), with bisabolol,

candinol, valerianol, and patchoulol accumulating at higher levels than aristolochene, valencene, selinene, vetispiradiene, and santalene.

These results indicate that solvent choice will need to be tailored to individual products if scaled processes for algal-produced terpenes are to be implemented. Our screening was conducted in small volume well-plates, in which the contact surface area of perfluorinated solvents is reduced by forming liquid beads under the aqueous phase. In scaled cultivation, the surface area for solvent milking can be improved, although chemical partitioning variability is likely to persist. Scaling these extraction methods for industrial applications presents challenges for which photobioreactors have not yet been optimized<sup>12, 33, 36, 38</sup>. To utilize engineered algae for heterologous terpene production, novel reactor designs that enable scalable culture-solvent interaction while maintaining optimal light-driven algae growth will be necessary.

## 2.5. Conclusions

This study demonstrates the feasibility of producing a diversity of chemically complex functionalized terpene products from the engineered algal cell. We show that functionalization of heterologous terpenoids can be achieved using soluble CYPs targeted to the plastid without the need for partner CPRs. While our investigation focused on STPs, this strategy could be applied to higher-value diterpene products as precursors for pharmaceutical production. The alga system offers a potential platform for rapid investigation of CYP activity, given the affordability of gene synthesis, quick generation of transformants within weeks, and straightforward analysis of terpenoid products. However, challenges and uncertainties remain in whether this can be scaled as a valuable production chassis for complex terpenoid compounds.

### 3. Materials and Methods

#### 3.1. Algae cultivation, plasmid design, transformation, and screening

Experiments used a *C. reinhardtii* strain derived from UPN22, modified for enhanced terpenoid biosynthesis through squalene synthase knockdown and  $\beta$ -carotene ketolase overexpression<sup>5, 6, 36, 38-41</sup>. Cultures were maintained in TAPhi-NO<sub>3</sub> medium under LED illumination (150  $\mu\text{mol m}^{-2} \text{s}^{-1}$ ). We selected ten sesquiterpene synthases (STPSs), including eight previously designed and two additional synthases - selinene synthase (UniProt: O64404) and vetispiradiene synthase (UniProt: A0A411G8M5)<sup>12, 15</sup>. Genes were codon-optimized and subjected to intron spreading to enable expression from the nuclear genome<sup>12</sup>.

We used three pOpt3-based STPS-containing construct designs: one for cytoplasmic expression with paromomycin selection (APHVIII) and two for chloroplast-targeted expression with hygromycin selection (APHVII)<sup>42-44</sup>. Chloroplast-targeted STPS constructs employed the *PsaD* promoter and chloroplast targeting peptide (CTP) with mKOok fluorescent protein and either *S. cerevisiae* (Erg20) or *E. coli* (ispA) farnesyl diphosphate synthase (FPPS). As previously reported, these FPPSs included a C-terminal stop codon to maintain activity<sup>45</sup>. Selected CYPs were optimized for nuclear genome expression and targeted to the algal plastid. We removed the TM domain from all CYP coding sequences to enable expression as soluble proteins in the plastid stroma. TM domains were identified through the TMHMM - 2.0 server and comparing AlphaFold models of each protein sequence to see low-structured N-terminal regions<sup>14, 18, 19</sup>. CYP-*C. reinhardtii* optimized sequences were subcloned into pOpt3-based expression constructs with the *PsaD* promoter and CTP, containing

the teal fluorescent protein (mTFP1) as a reporter and selection for zeocin resistance (shBle). All constructs were synthesized *de novo* and subcloned by Genscript (Piscataway, NJ, USA) (SI Appendix, Table S1, and File S1).

*C. reinhardtii* nuclear genome transformation used linearized plasmid DNA (restriction enzymes: *Xba*I and *Kpn*I) via a glass-bead protocol, with 10 µg DNA per transformation<sup>46</sup>. After an 8-hour recovery in liquid TAPhi-NO<sub>3</sub> medium<sup>47</sup> under low light, cells were plated on a medium containing spectinomycin (200 µg mL<sup>-1</sup>) plus paromomycin (10 µg mL<sup>-1</sup>), hygromycin B (15 µg mL<sup>-1</sup>), or zeocin (15 µg mL<sup>-1</sup>), individually or in combinations, matching the desired selection. Plates were exposed to continuous light for 7 days before colony selection. A PIXL colony-picking robot (Singer Instruments, UK) transferred up to 384 colonies per transformation event onto TAPhi-NO<sub>3</sub> agar plates. After 3 days, a ROTOR robot (Singer Instruments, UK) duplicated colonies onto new plates containing amido black (150 µg mL<sup>-1</sup>) for fluorescence screening<sup>15</sup>. We selected transformants exhibiting intense fluorescent-protein signals (SI Appendix, Fig. S1–S4) and transferred them to 12-well microtiter plates containing 2 mL liquid TAPhi-NO<sub>3</sub> medium, cultured with agitation at 160 rpm for subsequent two-phase cultivation and solvent analysis<sup>12, 45</sup>.

### 3.2. Capture of algal-produced sesquiterpenoids and their analysis by GC-FID/MS

We quantified sesquiterpenoid production using a two-phase cultivation system as described previously<sup>12, 33</sup>. Four transformants were selected based on fluorescence and analyzed in triplicate. Cultures were grown in 6-well microtiter plates containing 4.5 mL TAPhi-NO<sub>3</sub> medium and 500 µL dodecane overlay (10% of total volume) for 7 days<sup>12, 15</sup>. To evaluate alternative perfluorocarbon (FCs) as

terpenoid extraction solvents<sup>12, 15, 45</sup>, we tested ten FCs alongside dodecane: CFL7160, CXFL-68, CFL3000A, CXFL-3288, FC-770, FC-3284, FC-43, FC-72, FC-40, and FC-3283 (Sigma-Aldrich, Germany; Acros Organics, Belgium; Hunan Chemfish Pharmaceutical Co., Ltd, China) (**SI Appendix, Table S5**). For these extractions, we used 1000  $\mu$ L of solvent (20% of total volume) with 4 mL cultures. Dodecane formed an upper 'overlay' while FCs formed 'underlays'. We quantified final culture volumes after cultivation to account for evaporation. After cultivation, the phases were separated by centrifugation at  $3500 \times g$  for 5 min. Both solvent fractions (FCs and dodecane) were transferred to GC vials for analysis. Cell density was measured by flow cytometry (**SI Appendix, File S7**)<sup>33</sup>.

We performed GC-MS/FID analysis as described<sup>45</sup> and processed chromatograms using MassHunter software (Agilent, Germany, version B.08.00). Compounds were identified by comparing mass spectra to the NIST Mass Spectral Library (National Institute of Standards and Technology, USA). For quantification, we used calibration curves (1 – 500  $\mu$ M) of purified standards in dodecane or FCs:  $\delta$ -guaiene, patchoulol,  $\alpha$ -santalene, valerianol,  $\alpha$ -bisabolol, valencene, and cedrene (Toronto Research Chemicals, Canada) (**SI Appendix, Fig. S5**). A standard terpene mixture (MetaSci, Canada) containing 98 terpenes at 1 mM in methanol ensured accurate identification and internal library calibration (**Fig. 6, SI Appendix, Table S6**).

### 3.3. Data analysis

Each experimental condition included three biological replicates per transformant, with experiments independently repeated to ensure reproducibility. Controls comprised the parental non-transformed *C. reinhardtii* strain and vector-only constructs with respective fluorescent reporters. We performed GC-MS/FID



373 measurements in triplicate, manually reviewing chromatograms for quality control.  
 374 Terpenoid extracts were analyzed using established methods<sup>12, 33, 34</sup>. We based  
 375 compound identification on retention index, match factor, and comparison to the  
 376 NIST library. We calculated mean production values and standard deviations for  
 377 quantitative analysis and performed descriptive statistics (**SI Appendix, Tables**  
 378 **S2–S5**). Statistical analyses used JMP v.16 (SAS Institute, NC) and R v.3.6.2 (R  
 379 Foundation for Statistical Computing, Austria). We visualized data using JMP v.16  
 380 and GraphPad Prism v.10.3 (GraphPad Software, USA). Diagrams and  
 381 illustrations were created using Affinity Designer v.2.5.3 (Serif Ltd., UK), chemical  
 382 structures were drawn with ChemDraw v.20.1 (PerkinElmer, MA, USA), and visual  
 383 elements were integrated using Affinity Publisher v.2.5.3 (Serif Ltd., WB, UK).

#### 4. Data availability

All data supporting the findings of this study are included in the article and SI Appendix. Source data and genetic files are available in DRYAD (<https://doi.org/10.5061/dryad.zgmsbccmz>). For review purposes, source data can be accessed via a temporary link (<https://rb.gy/lpdr3a>).

#### 5. Acknowledgments

This work received support from King Abdullah University of Science and Technology competitive research grant 4715 and baseline research funding to KJL. SG and KJL would like to express their gratitude to Dr. Ahmed Alfahad of King Abdulaziz City for Science and Technology (KACST), who found and suggested several terpene synthases and cytochrome P450 enzymes used in this work.

## 6. References

1. Brock, N. L.; Dickschat, J. S., Biosynthesis of Terpenoids. In *Natural Products*, 2013; pp 2693-2732.
2. Bohlmann, J.; Keeling, C. I., Terpenoid biomaterials. *Plant J* **2008**, *54* (4), 656-69.
3. Tholl, D., Biosynthesis and biological functions of terpenoids in plants. *Adv Biochem Eng Biotechnol* **2015**, *148*, 63-106.
4. Cheng, A. X.; Lou, Y. G.; Mao, Y. B.; Lu, S.; Wang, L. J.; Chen, X. Y., Plant terpenoids: Biosynthesis and ecological functions. *J Integr Plant Biol* **2007**, *49* (2), 179-186.
5. Lecourt, M.; Antoniotti, S., Chemistry, Sustainability and Naturality of Perfumery Biotech Ingredients. *ChemSusChem* **2020**, *13* (21), 5600-5610.
6. Lohr, M.; Schwender, J.; Polle, J. E., Isoprenoid biosynthesis in eukaryotic phototrophs: a spotlight on algae. *Plant Sci* **2012**, *185-186*, 9-22.
7. Lauersen, K. J., Eukaryotic microalgae as hosts for light-driven heterologous isoprenoid production. *Planta* **2019**, *249* (1), 155-180.
8. Arendt, P.; Pollier, J.; Callewaert, N.; Goossens, A., Synthetic biology for production of natural and new-to-nature terpenoids in photosynthetic organisms. *Plant J* **2016**, *87* (1), 16-37.
9. Tholl, D., Terpene synthases and the regulation, diversity and biological roles of terpene metabolism. *Curr Opin Plant Biol* **2006**, *9* (3), 297-304.
10. Pateraki, I.; Heskes, A. M.; Hamberger, B., Cytochromes P450 for terpene functionalisation and metabolic engineering. *Adv Biochem Eng Biotechnol* **2015**, *148*, 107-39.
11. Zheng, S.; Guo, J.; Cheng, F.; Gao, Z.; Du, L.; Meng, C.; Li, S.; Zhang, X., Cytochrome P450s in algae: Bioactive natural product biosynthesis and light-driven bioproduction. *Acta Pharm Sin B* **2022**, *12* (6), 2832-2844.
12. Gutiérrez, S.; Overmans, S.; Wellman, G. B.; Samaras, V. G.; Oviedo, C.; Gede, M.; Szekely, G.; Lauersen, K. J., A synthetic biology and green bioprocess approach to recreate agarwood sesquiterpenoid mixtures. *Green Chemistry* **2024**, *26* (5), 2577-2591.
13. Yahya, R. Z.; Wellman, G. B.; Overmans, S.; Lauersen, K. J., Engineered production of isoprene from the model green microalga *Chlamydomonas reinhardtii*. *Metab Eng Commun* **2023**, *16*, e00221.
14. Wichmann, J.; Eggert, A.; Elbourne, L. D. H.; Paulsen, I. T.; Lauersen, K. J.; Kruse, O., Farnesyl pyrophosphate compartmentalization in the green microalga *Chlamydomonas reinhardtii* during heterologous (E)-alpha-bisabolene production. *Microb Cell Fact* **2022**, *21* (1), 190.
15. Abdallah, M. N.; Wellman, G. B.; Overmans, S.; Lauersen, K. J., Combinatorial Engineering Enables Photoautotrophic Growth in High Cell Density Phosphite-Buffered Media to Support Engineered *Chlamydomonas reinhardtii* Bio-Production Concepts. *Front Microbiol* **2022**, *13*, 885840.

- 438 16. Perozeni, F.; Baier, T., Current Nuclear Engineering Strategies in the Green  
439 Microalga *Chlamydomonas reinhardtii*. *Life (Basel)* **2023**, *13* (7).
- 440 17. Jacobebbinghaus, N.; Lauersen, K. J.; Kruse, O.; Baier, T., Bicistronic  
441 expression of nuclear transgenes in *Chlamydomonas reinhardtii*. *The Plant*  
442 *Journal* **2024**, *118* (5), 1400-1412.
- 443 18. Wichmann, J.; Baier, T.; Wentnagel, E.; Lauersen, K. J.; Kruse, O.,  
444 Tailored carbon partitioning for phototrophic production of (E)-alpha-bisabolene  
445 from the green microalga *Chlamydomonas reinhardtii*. *Metab Eng* **2018**, *45*, 211-  
446 222.
- 447 19. Lauersen, K. J.; Wichmann, J.; Baier, T.; Kampranis, S. C.; Pateraki, I.;  
448 Moller, B. L.; Kruse, O., Phototrophic production of heterologous diterpenoids and  
449 a hydroxy-functionalized derivative from *Chlamydomonas reinhardtii*. *Metab Eng*  
450 **2018**, *49*, 116-127.
- 451 20. Lauersen, K. J.; Baier, T.; Wichmann, J.; Wordenweber, R.; Mussnug,  
452 J. H.; Hubner, W.; Huser, T.; Kruse, O., Efficient phototrophic production of a  
453 high-value sesquiterpenoid from the eukaryotic microalga *Chlamydomonas*  
454 *reinhardtii*. *Metab Eng* **2016**, *38*, 331-343.
- 455 21. Schewe, H.; Mirata, M. A.; Schrader, J., Bioprocess engineering for  
456 microbial synthesis and conversion of isoprenoids. *Adv Biochem Eng Biotechnol*  
457 **2015**, *148*, 251-86.
- 458 22. Cheah, L. C.; Liu, L.; Stark, T.; Plan, M. R.; Peng, B.; Lu, Z.; Schenk,  
459 G.; Sainsbury, F.; Vickers, C. E., Metabolic flux enhancement from the  
460 translational fusion of terpene synthases is linked to terpene synthase  
461 accumulation. *Metab Eng* **2023**, *77*, 143-151.
- 462 23. Inckemann, R.; Chotel, T.; Brinkmann, C. K.; Burgis, M.; Andreas, L.;  
463 Baumann, J.; Sharma, P.; Klose, M.; Barrett, J.; Ries, F.; Paczia, N.; Glatte,  
464 T.; Willmund, F.; Mackinder, L. C. M.; Erb, T. J., *Advancing chloroplast synthetic*  
465 *biology through high-throughput plastome engineering of Chlamydomonas*  
466 *reinhardtii*. 2024.
- 467 24. Diaz-Chavez, M. L.; Moniodis, J.; Madilao, L. L.; Jancsik, S.; Keeling, C.  
468 I.; Barbour, E. L.; Ghisalberti, E. L.; Plummer, J. A.; Jones, C. G.; Bohlmann, J.,  
469 Biosynthesis of Sandalwood Oil: *Santalum album* CYP76F cytochromes P450  
470 produce santalols and bergamotol. *PLoS One* **2013**, *8* (9), e75053.
- 471 25. Villa-Ruano, N.; Pacheco-Hernández, Y.; Lozoya-Gloria, E.; Castro-  
472 Juárez, C. J.; Mosso-Gonzalez, C.; Ramirez-Garcia, S. A., Cytochrome P450 from  
473 Plants: Platforms for Valuable Phytopharmaceuticals. *Tropical Journal of*  
474 *Pharmaceutical Research* **2015**, *14* (4), 731-742.
- 475 26. Hu, B.; Zhao, X.; Wang, E.; Zhou, J.; Li, J.; Chen, J.; Du, G., Efficient  
476 heterologous expression of cytochrome P450 enzymes in microorganisms for the  
477 biosynthesis of natural products. *Crit Rev Biotechnol* **2023**, *43* (2), 227-241.
- 478 27. Nowrouzi, B.; Rios-Solis, L., Redox metabolism for improving whole-cell  
479 P450-catalysed terpenoid biosynthesis. *Crit Rev Biotechnol* **2022**, *42* (8), 1213-  
480 1237.

481 28. Meng, X.; Liu, H.; Xu, W.; Zhang, W.; Wang, Z.; Liu, W., Metabolic  
482 engineering *Saccharomyces cerevisiae* for de novo production of the  
483 sesquiterpenoid (+)-nootkatone. *Microb Cell Fact* **2020**, *19* (1), 21.

484 29. Ouyang, X.; Cha, Y.; Li, W.; Zhu, C.; Zhu, M.; Li, S.; Zhuo, M.; Huang,  
485 S.; Li, J., Stepwise engineering of *Saccharomyces cerevisiae* to produce (+)-  
486 valencene and its related sesquiterpenes. *RSC Adv* **2019**, *9* (52), 30171-30181.

487 30. Gong, B.; Liang, X.; Li, Y.; Xiao, Q.; Yang, P.; Wu, Y., Expression and  
488 Purification of Cytochrome P450 55B1 from *Chlamydomonas reinhardtii* and Its  
489 Application in Nitric Oxide Biosensing. *Appl Biochem Biotechnol* **2018**, *184* (1),  
490 102-112.

491 31. Gavira, C.; Hofer, R.; Lesot, A.; Lambert, F.; Zucca, J.; Werck-Reichhart,  
492 D., Challenges and pitfalls of P450-dependent (+)-valencene bioconversion by  
493 *Saccharomyces cerevisiae*. *Metab Eng* **2013**, *18*, 25-35.

494 32. Findinier, J.; Joubert, L.-M.; Schmid, M. F.; Malkovskiy, A.; Chiu, W.;  
495 Burlacot, A.; Grossman, A. R., Dramatic Changes in Mitochondrial Subcellular  
496 Location and Morphology Accompany Activation of the CO<sub>2</sub> Concentrating  
497 Mechanism. *bioRxiv* **2024**.

498 33. Overmans, S.; Lauersen, K. J., Biocompatible fluorocarbon liquid underlays  
499 for in situ extraction of isoprenoids from microbial cultures. *RSC Adv* **2022**, *12* (26),  
500 16632-16639.

501 34. Overmans, S.; Ignacz, G.; Beke, A. K.; Xu, J. J.; Saikaly, P. E.; Szekely,  
502 G.; Lauersen, K. J., Continuous extraction and concentration of secreted  
503 metabolites from engineered microbes using membrane technology. *Green*  
504 *Chemistry* **2022**, *24* (14), 5479-5489.

505 35. Wobbe, L.; Bassi, R.; Kruse, O., Multi-level light capture control in plants  
506 and green algae. *Trends in Plant Science* **2016**, *21* (1), 55-68.

507 36. de Freitas, B. B.; Overmans, S.; Medina, J. S.; Hong, P. Y.; Lauersen, K.  
508 J., Biomass generation and heterologous isoprenoid milking from engineered  
509 microalgae grown in anaerobic membrane bioreactor effluent. *Water Res* **2023**,  
510 *229*, 119486.

511 37. Eppink, M. H. M.; Olivieri, G.; Reith, H.; van den Berg, C.; Barbosa, M.  
512 J.; Wijffels, R. H., From Current Algae Products to Future Biorefinery Practices: A  
513 Review. *Adv Biochem Eng Biotechnol* **2019**, *166*, 99-123.


514 38. Li, T.; Liu, X.; Xiang, H.; Zhu, H.; Lu, X.; Feng, B., Two-Phase  
515 Fermentation Systems for Microbial Production of Plant-Derived Terpenes.  
516 *Molecules* **2024**, *29* (5).

517 39. Lindstrom, A. B.; Strynar, M. J.; Libelo, E. L., Polyfluorinated compounds:  
518 past, present, and future. *Environ Sci Technol* **2011**, *45* (19), 7954-61.

519 40. Carsanba, E.; Pintado, M.; Oliveira, C., Fermentation Strategies for  
520 Production of Pharmaceutical Terpenoids in Engineered Yeast. *Pharmaceuticals*  
521 *(Basel)* **2021**, *14* (4).

41. Burger, P.; Plainfosse, H.; Brochet, X.; Chemat, F.; Fernandez, X.,  
Extraction of Natural Fragrance Ingredients: History Overview and Future Trends.  
*Chem Biodivers* **2019**, *16* (10), e1900424.
42. Baier, T.; Jacobebbinghaus, N.; Einhaus, A.; Lauersen, K. J.; Kruse, O.,  
Introns mediate post-transcriptional enhancement of nuclear gene expression in  
the green microalga *Chlamydomonas reinhardtii*. *PLoS Genet* **2020**, *16* (7),  
e1008944.
43. Baier, T.; Wichmann, J.; Kruse, O.; Lauersen, K. J., Intron-containing algal  
transgenes mediate efficient recombinant gene expression in the green microalga  
*Chlamydomonas reinhardtii*. *Nucleic Acids Res* **2018**, *46* (13), 6909-6919.
44. Jaeger, D.; Baier, T.; Lauersen, K. J., Intronserter, an advanced online tool  
for design of intron containing transgenes. *Algal Research-Biomass Biofuels and  
Bioproducts* **2019**, *42*.
45. Gutierrez, S.; Wellman, G. B.; Lauersen, K. J., Teaching an old 'doc' new  
tricks for algal biotechnology: Strategic filter use enables multi-scale fluorescent  
protein signal detection. *Front Bioeng Biotechnol* **2022**, *10*, 979607.
46. Hallgren, J.; Tsirigos, K. D.; Pedersen, M. D.; Almagro Armenteros, J. J.;  
Marcatili, P.; Nielsen, H.; Krogh, A.; Winther, O., DeepTMHMM predicts alpha  
and beta transmembrane proteins using deep neural networks. *BioRxiv* **2022**,  
2022.04.08.487609.
47. Kindle, K. L.; Schnell, R. A.; Fernandez, E.; Lefebvre, P. A., Stable nuclear  
transformation of *Chlamydomonas* using the *Chlamydomonas* gene for nitrate  
reductase. *J Cell Biol* **1989**, *109* (6 Pt 1), 2589-601.


7. Figures and Tables






548 **Fig. 1. Genetic constructs and sesquiterpenoid production in engineered**  
549 ***C. reinhardtii* strains.** (A-C) Schematic representation of genetic constructs for  
550 sesquiterpenoid production in *C. reinhardtii*. Constructs include sesquiterpene  
551 synthases (STPS) fused to fluorescent protein reporters (FP) and farnesyl  
552 pyrophosphate synthases (FPPS) targeted to: (A) cytoplasm, (B) plastid with  
553 *Erg20* FPPS (*S. cerevisiae*), and (C) plastid with *ispA* FPPS (*E. coli*). Promoters:  
554 H-β (heat-shock protein/beta-tubulin), pPsaD (photosystem I subunit II promoter),  
555 H (heat-shock protein 70S promoter), R (RuBisCO small subunit 2 promoter). CTP:  
556 chloroplast transit peptide (PsaD). RBCS intron 1 (i1) and intron 2 (i2) are spread  
557 throughout the coding sequences of optimized genes. FDX: ferredoxin 1  
558 terminator. Inset: Engineered *C. reinhardtii* strain with chloroplast (brown),  
559 indicating modified carotenoid synthesis; letters indicate intended localization of  
560 recombinant enzyme products. (D) Chromatograms of sesquiterpenoid products  
561 from each STPS expression, compared to a parental strain negative control  
562 extract. Black dots indicate intended sesquiterpenoid products. (E)  
563 Sesquiterpenoid yields (μg/L culture) for each construct. Data for genetic  
564 constructs and GC-MS/FID can be found in **SI Appendix Tables S1–S3 and Files**  
565 **S1–S4.**






566

Fig. 2. Plastid-targeted sesquiterpenoid biosynthesis and functionalization by cytochrome P450 enzymes in *C. reinhardtii*. Sesquiterpene synthases (STPS) and cytochrome P450 enzymes (CYPs) were targeted to the algal chloroplast. Each STPS construct included C-terminal ScErg20 FPPS, while CYPs were co-expressed through plastid targeting and without transmembrane domains. (A) GC-MS chromatograms of dodecane extracts from *C. reinhardtii* strains expressing plastid localized STPS and CYP combinations, numbers indicate specific compounds identified by MS. (B) Quantitative analysis of sesquiterpenoid production based on GC-FID data. Circles: sum of peak areas for sesquiterpenoids; triangles: sum of peak areas for modified sesquiterpenoids. Data represent mean  $\pm$  SD (n=12, 4 transformants  $\times$  3 biological replicates). (C) Functionalization efficiency (%) of each CYP, calculated as the fraction of functionalized sesquiterpenoids from total sesquiterpenoids. Circles represent individual transformants. Compounds: [1] Aristolene, [2] Aristolochene, [3] Aristolochene, [4] Valencene, [5] Nootkatone, [6]  $\alpha$ -Santalene, [7] Bergamotol, [8] Santalol, [9]  $\alpha$ -Cadinene, [10]  $\delta$ -Cadinene, [11]  $\beta$ -Cadinene, [12] Muurolene, [13] Muurolol, [14]  $\tau$ -Cadinol, [15]  $\alpha$ -Guaiene, [16]  $\beta$ -Guaiene, [17]  $\alpha$ -Humulene, [18]  $\delta$ -Guaiene, [19] Alloaromadendrene, [20]  $\alpha$ -Guaiol, [21]  $\beta$ -Guaiol, [22] Globulol, [23] Rotundone, [24] Alloaromadendrene oxide. GC-MS/FID data in SI Appendix File S5, Tables S3, and Fig. S6–S7.




587

588 Fig. 3. Relative abundance of sesquiterpenoids produced in *C. reinhardtii* with  
 589 different cytochrome P450s (CYPs). Heat map showing the relative abundance  
 590 of sesquiterpenoid compounds based on GC-FID response. Columns represent  
 591 sesquiterpene synthase and CYP combinations. Color intensity indicates relative  
 592 abundance: red (high) to blue (low). Sesquiterpenoid compounds identified by  
 593 MS are listed on the right with corresponding numbers. GC-MS/FID data in SI  
 594 Appendix File S5, Table S3, and Fig. S6.




**Fig. 4. Sesquiterpenoid compounds produced from farnesyl pyrophosphate (FPP) from the *C. reinhardtii* plastid.** Illustration of sesquiterpenoid chemical structures identified in this work. Colored sections depict distinct sesquiterpenoid classes produced through the action of specific sesquiterpene synthases and cytochrome P450 enzymes. Compounds are labeled with unique identifiers corresponding to their structures: Aristolene [01], Aristolochene [02], Aristolochone [03], Valencene [04], Nootkatone [05], α-Santalene [06], Bergamotol [07], Santalol [08], α-Cadinene [09], δ-Cadinene [10], β-Cadinene [11], Muurolene [12], Muurolol [13], τ-Cadinol [14], α-Guaiene [15], β-Guaiene [16], α-Humulene [17], δ-Guaiene [18], Alloaromadendrene [19], α-Guaiol [20], β-Guaiol [21], Globulol [22], Rotundone [23], and Alloaromadendrene oxide [24]. GC-MS/FID data in SI Appendix File S5, Tables S7–S8.



608

609 **Fig 5. Carbon source effects on plastid-targeted sesquiterpenoid biosynthesis**  
610 **and functionalization in *C. reinhardtii*.** GC-MS/FID analysis of dodecane overlay  
611 samples for sesquiterpenoid species accumulated by *C. reinhardtii* expressing  
612 different STPSs (B02, B03, B06, B08, B09) and corresponding cytochrome P450s  
613 (CYP02, CYP05, CYP09, CYP10, CYP12) when cultivated with three carbon  
614 source conditions: CO<sub>2</sub>, acetate, or CO<sub>2</sub>+acetate. Black dots represent  
615 sesquiterpenoid compounds; black triangles indicate functionalized derivatives.  
616 Relative abundance plots quantify production levels under each condition. **(A)**  
617 Aristolochene synthase (B02) + CYP02; **(B)** Valencene synthase (B03) + CYP05;  
618 **(C)** Santalene synthase (B06) + CYP09; **(D)** Cadinol synthase (B08) + CYP10; **(E)**  
619 Guaiene synthase (B09) + CYP12. For each panel, chromatograms (left) show  
620 product retention times; bar graphs (right) depict relative abundance. GC-MS/FID  
621 data in SI Appendix File S6, Tables S6–S8.



622  
623 Fig 6. Sesquiterpenoid milking efficiencies using different perfluorinated  
624 solvents on engineered *C. reinhardtii*. Heat map comparing extraction  
625 capacities of fluorinated solvents relative to dodecane for various sesquiterpenoid  
626 compounds. Solvents tested: FC-40, FC-770, FC-3284 (perfluoro-n-  
627 dibutylmethylamine), CFL7160 (perfluoro noeny trifluoroethyl ether), CXFL-3288  
628 (perfluorotripropylamine), CXFL-68 (perfluorotributylamine), CFL3000A  
629 (hexafluoropropene trimer), FC-43, FC-72 (perfluoro-n-dibutylmethylamine), and  
630 FC-3283 (perfluorotripropylamine). Color intensity indicates extraction capacity  
631 (blue: 0%, red: 40%). GC-MS/FID data in SI Appendix Table S5.